In October, Andy Holt, Chief Commercial Officer at Viralgen, provided attendees of Meeting on the Mesa 2025 with an update on three of the company’s latest initiatives to help innovators advance their gene therapies more efficiently:
-
Plasmid Services: In-house pDNA manufacturing of transgenes to complement the company’s existing expertise in developing Rep/Cap and helper plasmids.
-
Development Services: Expanded capabilities in commercialization, with a platform approach that helps de-risk and accelerate the process by cross-referencing data across thousands of batches of AAV.
-
COGs Reduction: Providing innovators who are pursuing commercialization for a product with larger indications an opportunity to dramatically reduce per-patient manufacturing costs.
Andy also described the latest releases of the company’s exclusive Aava™ platform – Gen 2.0 (Mendi) and Gen 3.0 (Iturri) – and how each is poised to help Viralgen clients capitalize on better predictability, superior speed and deeper data.
